Among these glucagon-like peptide-1 receptor agonists (GLP-1 RAs), currently marketed for glycaemic control in type 2 diabetes mellitus (T2DM) and for weight loss [2], offer a novel mechanism to modify neurotoxicity in individuals at-risk for AD. Here, GLP1R is linked to type 2 diabetes mellitus.